Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Syndax Pharmaceuticals (SNDX) Capital Expenditures (2016 - 2025)

Syndax Pharmaceuticals (SNDX) has 5 years of Capital Expenditures data on record, last reported at $56000.0 in Q4 2025.

  • For Q4 2025, Capital Expenditures changed N/A year-over-year to $56000.0; the TTM value through Dec 2025 reached $70000.0, up 400.0%, while the annual FY2025 figure was $187000.0, N/A changed from the prior year.
  • Capital Expenditures reached $56000.0 in Q4 2025 per SNDX's latest filing, up from $14000.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $56000.0 in Q4 2025 and bottomed at $56000.0 in Q4 2025.